CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 44 enrolled
Drug / intervention
Renal denervationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04264403
NCT04264403N/ACompleted
CompareCT.gov

Effect of Renal Denervation on Blood Pressure in Patients With Chronic Kidney Disease and Uncontrolled Hypertension

University of Erlangen-Nürnberg Medical School·interventional·Posted Feb 11, 2020·Updated Apr 30, 2026

In Brief

A clinical study evaluating Renal denervation for Uncontrolled Hypertension and 2 related conditions. Completed, enrolled 44 participants across 4 sites.

Detailed Summary

RDN-CKD Study is a prospective, randomized (1:1, central randomization), double-blind (unblinded interventionalist and blinded study team at each center), sham controlled, multicenter feasibility study. The purpose of the RDN-CKD Study is to demonstrate that renal denervation (RDN) effectively reduces 24-h ambulatory BP in 80 patients with chronic kidney disease (CKD) stage 3a or 3b.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUncontrolled Hypertension, Renal Denervation, Chronic Kidney Disease stage3
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedFeb 11, 2020
Enrollment StartJan 23, 2020
Primary CompletionNov 23, 2023
Study CompletionApr 16, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.4 years ago

Interventions

Renal denervationdevice

The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.